Biotech Values

[DewDiligence]

Re: IDIX / IDX899 prospective partners

>Gilead is the "lead suspect," according to an analyst who cited the fact that Sustiva, an NNRTI that is part of the company's triple combination regimen, will go off patent in 2013. Merck, Bristol-Myers Squibb and perhaps GlaxoSmithKline could also be potential partners for IDX-899, the analyst noted.<

This write-up is OK as far as it goes, but it misses what was probably the biggest revelation from IDIX’s recent CC: that each of the prospective partners is interested in co-formulating IDX899 with the partner’s own HIV drug(s). In other words, none of the prospective partners is interested in IDX899 as a standalone product.